Companies › Hangzhou Sumgen Biotech
3 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SG301 SC | – | Phase 3 | Relapsed/Refractory Multiple Myeloma; Primary Immune Thrombocytopenia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory Multiple Myeloma | Dec 2026 |
| SG1906 anti-CLDN18.2 antibody or antibody-drug conjugate | CLDN18 | Phase 1 | Locally Advanced Unresectable or Metastatic Solid Tumors | Feb 2027 |
| SG2918 | – | Phase 1 | Relapsed/Refractory Multiple Myeloma | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04684108 | SG301 SC | Phase 1 | Relapsed or Refractory Multiple Myeloma | Oncology | Dec 2026 |
| NCT05857332 | SG1906 | Phase 1 | Locally Advanced Unresectable or Metastatic Solid Tumors | Oncology | Feb 2027 |
| NCT06508983 | SG301 SC | Phase 3 | Relapsed/Refractory Multiple Myeloma | Oncology | Mar 2027 |
| NCT07710248 | SG301 SC | Phase 2 | Primary Immune Thrombocytopenia | Hematology | May 2027 |
| NCT07454187 | SG2918 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Oncology | Sep 2027 |
| NCT07447986 | SG301 SC | Phase 2 | Systemic Lupus Erythematosus (SLE) | Immunology | Sep 2027 |
Biokin (Shanghai) Biopharmaceutical LaNova Medicines Zhejiang Alentis Therapeutics Antengene Biologics Dong-A ST
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.